Suppr超能文献

肾功能不全、CHADS评分与非瓣膜性心房颤动患者抗凝治疗的依从性

Renal Dysfunction, CHADS Score, and Adherence to the Anticoagulant Treatment in Nonvalvular Atrial Fibrillation.

作者信息

Sun Yihong, Wang Yitong, Jiang Juan, Wang Lina, Hu Dayi

机构信息

1 Peking University People's Hospital, Beijing, China.

出版信息

Clin Appl Thromb Hemost. 2017 Apr;23(3):248-254. doi: 10.1177/1076029615611250. Epub 2016 Jul 9.

Abstract

We investigated the risk of stroke associated with renal dysfunction and the impact of warfarin therapies in Chinese patients with nonvalvular atrial fibrillation (NVAF). Information was collected on age, sex, height, weight, type of atrial fibrillation, and serum creatinine within the previous 6 months, together with the variables needed to calculate the CHADS score. For patients not taking warfarin, reasons why not were recorded. Three thousand seventeen eligible patients with NVAF, mean (1 standard deviation [SD]) age of 67.7 (13.0) years, from 50 Chinese hospitals were included from May 2012 to October 2012, with a mean (1SD) CHADS score of 2.0 (1.5). Of these, 58.3% were male and 86.2% were at high risk of stroke with a CHADS score ≥1. Only 42.6% were on warfarin, and 22.5% of the patients had moderate or severe renal impairment (estimated glomerular filtration rate < 60 mL/min/1.73 m). After adjustment for the CHADS score, renal dysfunction remained moderately but significantly associated with the risk of stroke/TIA (odds ratio = 1.005, 95% confidence interval: 1.002-1.009, P = .002). There was, however, no significant difference in anticoagulant usage between patients with or without impaired renal dysfunction. The most common anticoagulant concerns were the low proportion of patients with regular international normalized ratio monitoring (43.0%) and the risk of bleeding (33.3%). Renal impairment was common and independently associated with the risk of cerebrovascular embolism in Chinese patients with NVAF but not independently related to underuse of anticoagulant treatment.

摘要

我们研究了肾功能不全与中国非瓣膜性心房颤动(NVAF)患者中风风险的相关性以及华法林治疗的影响。收集了患者的年龄、性别、身高、体重、房颤类型、过去6个月内的血清肌酐水平,以及计算CHADS评分所需的变量。对于未服用华法林的患者,记录未服用的原因。2012年5月至2012年10月,从50家中国医院纳入了3017例符合条件的NVAF患者,平均(1个标准差[SD])年龄为67.7(13.0)岁,平均(1SD)CHADS评分为2.0(1.5)。其中,58.3%为男性,86.2%的患者CHADS评分≥1,属于中风高危人群。只有42.6%的患者服用华法林,22.5%的患者有中度或重度肾功能损害(估计肾小球滤过率<60 mL/min/1.73 m²)。调整CHADS评分后,肾功能不全仍与中风/短暂性脑缺血发作风险呈中度但显著的相关性(优势比=1.005,95%置信区间:1.002 - 1.009,P = 0.002)。然而,肾功能不全患者与无肾功能损害患者在抗凝药物使用方面无显著差异。最常见的抗凝相关问题是定期国际标准化比值监测的患者比例较低(43.0%)和出血风险(33.3%)。在中国NVAF患者中,肾功能损害很常见,且与脑血管栓塞风险独立相关,但与抗凝治疗使用不足无独立关联。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验